HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women

Resource Utilization and Costs of Care prior to ART Initiation for Pediatric Patients in Zambia
August 3, 2022
Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort study
August 3, 2022

HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women

Leave a Reply

Your email address will not be published. Required fields are marked *

Facebook
Twitter
YouTube
LinkedIn
Instagram